These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 39198739)

  • 1. Long-acting injectable antiretroviral treatment: experiences of people with HIV and their healthcare providers in Uganda.
    Zakumumpa H; Alinaitwe A; Kyomuhendo M; Nakazibwe B
    BMC Infect Dis; 2024 Aug; 24(1):876. PubMed ID: 39198739
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Perspectives Among Health Care Providers and People with HIV on the Implementation of Long-Acting Injectable Cabotegravir/Rilpivirine for Antiretroviral Therapy in Florida.
    Fisk-Hoffman RJ; Ranger SS; Gracy A; Gracy H; Manavalan P; Widmeyer M; Leeman RF; Cook RL; Canidate S
    AIDS Patient Care STDS; 2024 Jun; 38(6):275-285. PubMed ID: 38686517
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High Acceptability and Perceived Feasibility of Long-Acting Injectable Antiretroviral Treatment Among People Living with HIV Who Are Viremic and Health Workers in Uganda.
    Kennedy CE; Zhao T; Vo AV; Nakubulwa R; Nabakka P; Jackson J; Rosen JG; Chang LW; Reynolds SJ; Quinn TC; Nakigozi G; Kigozi G; Kagaayi J; Nalugoda F; Ddaaki WG; Grabowski MK; Nakyanjo N
    AIDS Patient Care STDS; 2023 Jun; 37(6):316-322. PubMed ID: 37294280
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-Acting Injectable ART in Practice: A Mixed Methods Implementation Study Assessing the Feasibility of Using LAI ART in High Risk Populations and At Alternative Low Barrier Care Sites.
    Fletcher L; Burrowes S; Sabin LL; McCann N; Khan GK; Ruiz-Mercado G; Johnson S; Kimmel SD; Pierre C; Drainoni ML
    AIDS Patient Care STDS; 2024 May; 38(5):221-229. PubMed ID: 38656905
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The potential role of long-acting injectable cabotegravir-rilpivirine in the treatment of HIV in sub-Saharan Africa: a modelling analysis.
    Phillips AN; Bansi-Matharu L; Cambiano V; Ehrenkranz P; Serenata C; Venter F; Pett S; Flexner C; Jahn A; Revill P; Garnett GP
    Lancet Glob Health; 2021 May; 9(5):e620-e627. PubMed ID: 33770513
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rilpivirine and cabotegravir trough concentrations in people with HIV on long-term treatment with long-acting injectable antiretrovirals.
    Cossu MV; Cattaneo D; Moschese D; Giacomelli A; Soloperto S; D'Avolio A; Antinori S; Gori A; Rizzardini G; Gervasoni C
    J Antimicrob Chemother; 2024 May; 79(5):1126-1132. PubMed ID: 38530862
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world use of long-acting cabotegravir and rilpivirine: 12-month results of the inJectable Antiretroviral therapy feasiBility Study (JABS).
    John M; Williams L; Nolan G; Bonnett M; Castley A; Nolan D
    HIV Med; 2024 Aug; 25(8):935-945. PubMed ID: 38644518
    [TBL] [Abstract][Full Text] [Related]  

  • 8. "I Feel Like I Don't Even Have HIV Anymore"-Facilitators, Barriers, and Experience regarding Use of Long-Acting Injectable Antiretroviral Therapy Among Persons with HIV in North Carolina.
    Agarwal H; Huffstetler HE; Lopez C; Go VF; Napravnik S; Farel CE; Rutstein SE
    AIDS Patient Care STDS; 2024 Jul; 38(7):324-329. PubMed ID: 38860413
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Switch to long-acting cabotegravir and rilpivirine in virologically suppressed adults with HIV in Africa (CARES): week 48 results from a randomised, multicentre, open-label, non-inferiority trial.
    Kityo C; Mambule IK; Musaazi J; Sokhela S; Mugerwa H; Ategeka G; Cresswell F; Siika A; Kosgei J; Shah R; Naidoo L; Opiyo K; Otike C; Möller K; Kaimal A; Wambui C; Van Eygen V; Mohammed P; Addo Boateng F; Paton NI;
    Lancet Infect Dis; 2024 Oct; 24(10):1083-1092. PubMed ID: 38821073
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study.
    Orkin C; Oka S; Philibert P; Brinson C; Bassa A; Gusev D; Degen O; García JG; Morell EB; Tan DHS; D'Amico R; Dorey D; Griffith S; Thiagarajah S; St Clair M; Van Solingen-Ristea R; Crauwels H; Ford SL; Patel P; Chounta V; Vanveggel S; Cutrell A; Van Eygen V; Vandermeulen K; Margolis DA; Smith KY; Spreen WR
    Lancet HIV; 2021 Apr; 8(4):e185-e196. PubMed ID: 33794181
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acceptability of Long-Acting Injectable Antiretroviral Therapy Among People with HIV Receiving Care at Three Ryan White Funded Clinics in the United States.
    Erguera XA; Koester KA; Diaz Tsuzuki M; Dance KV; Flores R; Kerman J; McNulty MC; Colasanti JA; Collins LF; Montgomery ET; Johnson MO; Sauceda JA; Christopoulos KA
    AIDS Behav; 2024 Jul; 28(7):2226-2238. PubMed ID: 38598026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential healthcare resource use and associated costs of every 2 month injectable cabotegravir plus rilpivirine long-acting regimen implementation in the Spanish National Healthcare System compared to daily oral HIV treatments.
    Aparicio LV; García VN; Hernández-Novoa B; Casado G; Jodar F; Pinel M; Velasco DC
    BMC Infect Dis; 2024 Aug; 24(1):775. PubMed ID: 39095714
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial.
    Margolis DA; Gonzalez-Garcia J; Stellbrink HJ; Eron JJ; Yazdanpanah Y; Podzamczer D; Lutz T; Angel JB; Richmond GJ; Clotet B; Gutierrez F; Sloan L; Clair MS; Murray M; Ford SL; Mrus J; Patel P; Crauwels H; Griffith SK; Sutton KC; Dorey D; Smith KY; Williams PE; Spreen WR
    Lancet; 2017 Sep; 390(10101):1499-1510. PubMed ID: 28750935
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acceptability and tolerability of long-acting injectable cabotegravir or rilpivirine in the first cohort of virologically suppressed adolescents living with HIV (IMPAACT 2017/MOCHA): a secondary analysis of a phase 1/2, multicentre, open-label, non-comparative dose-finding study.
    Lowenthal ED; Chapman J; Ohrenschall R; Calabrese K; Baltrusaitis K; Heckman B; Yin DE; Agwu AL; Harrington C; Van Solingen-Ristea RM; McCoig CC; Adeyeye A; Kneebone J; Chounta V; Smith-Anderson C; Camacho-Gonzalez A; D'Angelo J; Bearden A; Crauwels H; Huang J; Buisson S; Milligan R; Ward S; Bolton-Moore C; Gaur AH; ;
    Lancet HIV; 2024 Apr; 11(4):e222-e232. PubMed ID: 38538161
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Perspectives of people living with HIV-1 on implementation of long-acting cabotegravir plus rilpivirine in US healthcare settings: results from the CUSTOMIZE hybrid III implementation-effectiveness study.
    Garris CP; Czarnogorski M; Dalessandro M; D'Amico R; Nwafor T; Williams W; Merrill D; Wang Y; Stassek L; Wohlfeiler MB; Sinclair GI; Mena LA; Thedinger B; Flamm JA; Benson P; Spreen WR
    J Int AIDS Soc; 2022 Sep; 25(9):e26006. PubMed ID: 36097674
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient-Reported Outcomes Through 1 Year of an HIV-1 Clinical Trial Evaluating Long-Acting Cabotegravir and Rilpivirine Administered Every 4 or 8 Weeks (ATLAS-2M).
    Chounta V; Overton ET; Mills A; Swindells S; Benn PD; Vanveggel S; van Solingen-Ristea R; Wang Y; Hudson KJ; Shaefer MS; Margolis DA; Smith KY; Spreen WR
    Patient; 2021 Nov; 14(6):849-862. PubMed ID: 34056699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Realizing the promise of long-acting antiretroviral treatment strategies for individuals with HIV and adherence challenges: an illustrative case series.
    Kilcrease C; Yusuf H; Park J; Powell A; Rn LJ; Rn JO; Lmsw BD; Weld ED; Dooley KE; Arrington-Sanders R; Agwu AL
    AIDS Res Ther; 2022 Nov; 19(1):56. PubMed ID: 36435793
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improving Adherence to the Target Window for Cabotegravir + Rilpivirine Long-Acting Injections Through the CHORUS™ App and Web Portal: A Cluster Randomized Trial.
    Wohlfeiler MB; Brunet L; Cochran Q; Fusco JS; Hsu RK; Fusco GP
    J Int Assoc Provid AIDS Care; 2024; 23():23259582241245223. PubMed ID: 38613372
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Experiences with long acting injectable ART: A qualitative study among PLHIV participating in a Phase II study of cabotegravir + rilpivirine (LATTE-2) in the United States and Spain.
    Kerrigan D; Mantsios A; Gorgolas M; Montes ML; Pulido F; Brinson C; deVente J; Richmond GJ; Beckham SW; Hammond P; Margolis D; Murray M
    PLoS One; 2018; 13(1):e0190487. PubMed ID: 29304154
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identifying Implementation Determinants and Strategies for Long-Acting Injectable Cabotegravir-Rilpivirine in People With HIV Who Are Virally Unsuppressed.
    Hickey MD; Grochowski J; Mayorga-Munoz F; Oskarsson J; Imbert E; Spinelli M; Szumowski JD; Appa A; Koester K; Dauria EF; McNulty M; Colasanti J; Havlir DV; Gandhi M; Christopoulos KA
    J Acquir Immune Defic Syndr; 2024 Jul; 96(3):280-289. PubMed ID: 38534179
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.